Adinolfi L E, Utili R, Andreana A, Tripodi M F, Rosario P, Mormone G, Ragone E, Pasquale G, Ruggiero G
Institute of Medical Therapy, Faculty of Medicine, Second University of Naples, Italy.
Eur J Gastroenterol Hepatol. 2000 Mar;12(3):299-304. doi: 10.1097/00042737-200012030-00007.
The aim of this study was to assess the relationship between HCV genotype and histological liver injury.
Prospective study on a cohort of patients with biopsy proven chronic hepatitis C.
University medical centre.
Enrolled were 324 consecutive patients (male 197, median age 52 years, range 19-68; chronic hepatitis, 224; cirrhosis, 100).
HCV genotype was determined by the INNO LiPA assay and HCV RNA levels by the bDNA assay. The histological features were scored according to the histology activity index.
The distribution of HCV genotypes was 1a, 4.6%; 1b, 52.4%; 2a/c, 27%; 3a, 8%; 4, 2%; mixed, 6%. Serum HCV RNA levels were similar for all genotypes. There was no difference in the distribution of HCV genotypes between patients with chronic hepatitis and those with cirrhosis. Patients with genotype 1b and those with type 2a/c showed a similar prevalence of cases of cirrhosis (33% versus 31%, respectively). In addition, in a subgroup of 102 patients with an established date of infection, the progression to cirrhosis occurred with a similar length of time for HCV type 1b and 2a/c (median 16 versus 15 years, respectively). Patients with HCV genotype 2a/c or mixed genotype showed a higher histology activity index than those with type 1b (P< 0.01), whereas there was no difference in the fibrosis score for the different genotypes. Patients with genotype 3a showed a significantly higher prevalence of steatosis compared to those infected with other genotypes. Alanine aminotransferase (ALT) values were higher in patients with HCV type 2a/c, 3a and mixed genotype than those with type 1 (P < 0.002).
The data indicate that there is no association between a particular HCV genotype and the progression to cirrhosis, and that specific genotypes are associated with distinct histopathological and biochemical manifestations although none of them is correlated with an increase of the fibrosis stage.
本研究旨在评估丙型肝炎病毒(HCV)基因型与肝脏组织学损伤之间的关系。
对一组经活检证实为慢性丙型肝炎患者的前瞻性研究。
大学医学中心。
纳入324例连续患者(男性197例,中位年龄52岁,范围19 - 68岁;慢性肝炎224例,肝硬化100例)。
采用INNO LiPA分析法测定HCV基因型,采用bDNA分析法测定HCV RNA水平。根据组织学活动指数对组织学特征进行评分。
HCV基因型分布为:1a型,4.6%;1b型,52.4%;2a/c型,27%;3a型,8%;4型,2%;混合型,6%。所有基因型的血清HCV RNA水平相似。慢性肝炎患者和肝硬化患者之间HCV基因型分布无差异。1b型和2a/c型患者的肝硬化患病率相似(分别为33%和31%)。此外,在102例有明确感染日期的患者亚组中,1b型和2a/c型HCV进展为肝硬化的时间相似(中位时间分别为16年和15年)。HCV 2a/c型或混合型患者的组织学活动指数高于1b型患者(P < 0.01),而不同基因型的纤维化评分无差异。与感染其他基因型的患者相比,3a型患者的脂肪变性患病率显著更高。HCV 2a/c型、3a型和混合型患者的丙氨酸氨基转移酶(ALT)值高于1型患者(P < 0.002)。
数据表明,特定的HCV基因型与肝硬化进展之间无关联,尽管没有一种基因型与纤维化阶段的增加相关,但特定基因型与不同的组织病理学和生化表现相关。